Compare Ecopetrol SA (EC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Sana Biotechnology Inc — how do they compare? Ecopetrol SA trades at $16.86 (market cap $33.69B), while Sana Biotechnology Inc trades at $3.81 (market cap $1.13B). The key difference: Ecopetrol SA is far larger — about 29.8× Sana Biotechnology Inc's market cap, and Ecopetrol SA pays a 3.82% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| EC | SANA | |
|---|---|---|
Market Cap | $33.69B | $1.13B |
Sector | Energy | Health |
52-Week High | $17.40 | $5.92 |
52-Week Low | $8.56 | $2.68 |
Enterprise Value | $63.86B | $1.05B |
Dividend Yield | 3.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $17.05, up 1.61% with a bullish technical signal from moving averages. The company reported mixed Q2 2026 earnings, beating EPS estimates but showing declining revenue trends from $119.69T in 2025 to $116.95T projected for 2026. Recent developments include a cybersecurity incident in July 2026 and ongoing acquisition activities in Brazil's energy sector through Brava Energia.
The stock presents a value opportunity with attractive valuation ratios (P/E 11.11, P/S 0.97) but faces headwinds from declining revenue and profit margins. Analyst consensus is cautious with a $15 price target below current levels, while institutional sentiment shows mixed ratings amid operational challenges and cybersecurity risks.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
